ClinicalTrials.gg
TerminatedNCT06423794Updated Dec 16, 2025

BHV-7000 Open-Label Extension Bipolar Mania Study

A Phase 2 interventional study of BHV-7000 in Bipolar Disorder, sponsored by Biohaven Therapeutics Ltd.. Terminated at 32 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Biohaven Therapeutics Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
Business Decision

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Enrollment
250th of 704
94 · median 58
Started
2024
with 33 others
Phase 2
92 of 837
9 open now
Registered
778th of 837
by date

Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 250th largest by enrollment of the 704 interventional ones that give a count, is one of 34 that started in 2024, is one of 92 in phase 2, and was the 778th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 837 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.

03

Conditions studied

  • Bipolar Disorder

Keywords

  • bipolar
  • mania
  • manic episode
  • manic state
  • bipolar disorder type 1
  • manic depressive
  • manic bipolar
  • mixed features
  • mixed episode
  • mixed mania
  • bipolar episode
  • bipolar disorder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Subjects must have successfully completed the parent study, BHV7000-204.
  2. must have a negative urine pregnancy test at Baseline visit.
  3. WOCBP must not be breastfeeding or lactating at Baseline visit or any point in the study.

Key Exclusion Criteria:

  1. Any medical condition, based on the judgement of the Investigator, that would confound the ability to adequately assess safety and efficacy outcome measures.
  2. Subjects who, in the opinion of the Investigator, will not be able to adhere to the Schedule of Assessments and/or may have difficulties complying with the treatment regimen over an extended duration of a long-term, outpatient study.
  3. Investigator deems subject at imminent risk of danger to others or themself.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    BHV-7000

    Drug: BHV-7000

Interventions

  • BHV-7000 75 mg taken once daily

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant Laboratory Abnormalities

    To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with grade 3 or 4 laboratory abnormalities.

    Time frame: Up to 52 weeks

  2. Number of Participants With Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and AEs judged to be related to study medication

    To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with SAEs, AEs leading to discontinuation, AEs judged to be related to study medication that are observed during the Double-blind Treatment Phase (21 days).

    Time frame: Up to 52 weeks

  3. Number of Participants With Vital Sign Abnormalities

    Time frame: Up to 52 weeks

  4. Number of Participants With Electrocardiogram (ECG) Abnormalities specific to QTc elevation

    Time frame: Up to 52 weeks

07

Study locations

32 sites
  • Pillar Clinical Research, LLC
    Bentonville, Arkansas 72712, United States
  • WIRG
    Little Rock, Arkansas 72211, United States
  • WRN
    Rogers, Arkansas 72758, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • CIT LA
    Bellflower, California 90706, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Cenexel CNS
    Garden Grove, California 92845, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • CIT IE
    Riverside, California 92506, United States
  • Cenexel CNS
    Torrance, California 90504, United States
  • Segal Trials - Larkin Behavioral Health Services-Inpatient & Early Phase Site
    Hollywood, Florida 33021, United States
  • Cenexel - RCA
    Hollywood, Florida 33024, United States
  • LCC Medical Research Inst
    Miami, Florida 33126, United States
  • Floridian Neuroscience Institute
    Miami Lakes, Florida 33016, United States
  • Segal Trials - Miami Lakes Medical Research-Inpatient & Early Phase Site
    Miami Lakes, Florida 33016, United States
  • Neuroscience Research Institute
    West Palm Beach, Florida 33407, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Pillar Clinical Research
    Chicago, Illinois 60641, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • Precise Clinical Research
    Flowood, Mississippi 39232, United States
  • Arch Clinical Trials
    St Louis, Missouri 63141, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • RBA
    Staten Island, New York 10329, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • NBCR
    North Canton, Ohio 44720, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • InSite Clinical Research, LLC
    DeSoto, Texas 75115, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Apr 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 21, 2024
StartActual
Jun 24, 2024
Primary completionActual
Apr 25, 2025
CompletionActual
Apr 25, 2025
Results delay requested
Dec 13, 2025
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06423794
Lead sponsor
Biohaven Therapeutics Ltd.
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Jun 24, 2024
Primary completion
Apr 25, 2025
Completion
Apr 25, 2025
Last update
Dec 16, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opakalim

Start the discussion